Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In-Tether Chiral Center Induced Helical Peptide Modulators Target p53-MDM2/MDMX and Inhibit Tumor Growth in Stem-Like Cancer Cell.

Theranostics - 1 Jan 2017

Hu Kuan, Yin Feng, Yu Mengyin, Sun Chengjie, Li Jingxu, Liang Yujie, Li Wenjun, Xie Mingsheng, Lao Yuanzhi, Liang Wei, Li Zi-Gang

Abstract excerpt

Inhibition of the interaction between p53 and MDM2/MDMX has attracted significant attention in anticancer therapy development. We designed a series of in-tether chiral center-induced helical stabilized peptides, among which MeR/PhR effectively reactivated p53. The activation of p53 inhibits cell proliferation and induces apoptosis in both the MCF-7 normal tumor cell line and the PA-1 pluripotent cancer cell line...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HCT116 Cells
Share to Immunoprecipitation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MCF-7 Cells

Share to Microscopy, Confocal

Share to Neoplastic Stem Cells

Share to Peptides

Share to Proto-Oncogene Proteins c-mdm2

Share to Ubiquitination

Source

Open in PubMed Open full text

Identifiers

PMID: 29158845
DOI: 10.7150/thno.19840
PMCID: PMC5695149

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In-Tether Chiral Center Induced Helical Peptide Modulators Target p53-MDM2/MDMX and Inhibit Tumor Growth in Stem-Like Cancer Cell.PMID 29158845Read ↗

Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site.Semantic proximity Read ↗

Chemical Variations on the p53 Reactivation ThemeSemantic proximity Read ↗

Targeting the MDM2 ‐ MDM4 interaction interface reveals an otherwise therapeutically active wild‐type p53 in colorectal cancerSemantic proximity Read ↗

A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability.Semantic proximity Read ↗

Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancerSemantic proximity Read ↗

Design-Rules for Stapled Alpha-Helical Peptides with On-Target In Vivo Activity: Application to Mdm2/X dual antagonistsSemantic proximity Read ↗

Peptide and protein chemistry approaches to study the tumor suppressor protein p53.Semantic proximity Read ↗

A stapled peptide inhibitor of MDM2 enables pharmacological activation of p53 in zebrafishSemantic proximity Read ↗

A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)Semantic proximity Read ↗

Molecular avenues in targeted doxorubicin cancer therapySemantic proximity Read ↗

Recent Synthetic Approaches towards Small Molecule Reactivators of p53.Semantic proximity Read ↗

The Structure‐Based Design of Mdm2/Mdmx–p53 Inhibitors Gets SeriousSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.